Evidence map›Paper›PMID 39770424›Full record

ArticlePharmaceuticals (Basel, Switzerland)2024

Study of Cytotoxicity of Spiro-Fused [3-Azabicyclo[3.1.0]hexane]oxindoles and Cyclopropa[a]pyrrolizidine-oxindoles Against Tumor Cell Lines.

Anton A Kornev, Stanislav V Shmakov, Alexander I Ponyaev, Alexander V Stepakov, Vitali M Boitsov

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Study of Cytotoxicity of Pyrrolo[3,4-International journal of molecular sciences · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Study of Cytotoxicity of 3-Azabicyclo[3.1.0]hexanes and Cyclopropa[International journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Anton A KornevLaboratory of Nanobiotechnologies, Saint-Petersburg National Research Academic University of the Russian Academy of Sciences, Saint Petersburg 194021, Russia.
Stanislav V ShmakovLaboratory of Nanobiotechnologies, Saint-Petersburg National Research Academic University of the Russian Academy of Sciences, Saint Petersburg 194021, Russia.
Alexander I PonyaevSaint-Petersburg State Institute of Technology, Saint Petersburg 190013, Russia.
Alexander V StepakovSaint-Petersburg State Institute of Technology, Saint Petersburg 190013, Russia.
Vitali M BoitsovLaboratory of Nanobiotechnologies, Saint-Petersburg National Research Academic University of the Russian Academy of Sciences, Saint Petersburg 194021, Russia.ORCID 0000-0002-4857-2046

Funding

Ministry of Education and Science of the Russian Federation FSRM-2023-0005, FSEN-2023-0002
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

1,3-dipolar cycloaddition3-spiro[3-azabicyclo[3.1.0]-hexane]oxindoleantiproliferative activityazomethine ylidescell cyclecell motilitycyclopropa[a]pyrrolizidine-2,3′-oxindolecyclopropenesmorphological changes (cytoskeleton)tumor cell lines

Identifiers

PMID39770424
PMCPMC11680018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.